10月18日，北极光投资企业 血霁生物 宣布自主研发的“全球新” Fisrt-in-Class细胞治疗产品XJ-MK-002 治疗先天性无巨核细胞性血小板减少症获得美国食品药品监督管理局（FDA）认证授予儿科罕见病资格认定（Rare ...

The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute ...

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Tuesday announced that the U.S. Food and ...

BOSTON–(BUSINESS WIRE)–#bpgbio—BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. The acquisition strengthens Lundbeck's pipeline with ...

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today ...

Belite Bio, Inc (NASDAQ: BLTE) ("Belite” or the "Company”), a clinical-stage biopharmaceutical drug development company ...